Key result
A hemodialysis patient with osteomyelitis due to vancomycin- and teicoplanin-resistant Enterococcus faecium was successfully treated with linezolid for 6 months despite hematological alterations.
Why the study?
Can long-term linezolid be safely and effectively used to treat osteomyelitis in a hemodialysis patient?
Case Report (n=1)
Can long-term linezolid be safely and effectively used to treat osteomyelitis in a hemodialysis patient?
Long-term linezolid treatment for osteomyelitis can be successful in hemodialysis patients with close monitoring for hematological adverse effects.
Supports potential for extended linezolid in hemodialysis osteomyelitis with hematologic monitoring; hypothesis-generating pending controlled data.
Anemia and/or thrombocytopenia are the most relevant adverse effects of linezolid treatment. We report the case of a patient under hemodialysis who developed osteomyelitis involving the amputation stump of the left limb due to a vancomycin-resistant and teicoplanin-resistant Enterococcus faecium successfully treated with linezolid for 6 months. Close monitorization of the patient probably contributed to maintenance of treatment with linezolid despite hematological alterations observed, which could be attributed to either the underlying patient's clinical condition or antimicrobial treatment.
No takes yet. Share an insight, caveat, or question.
Berenguer et al. (2012) conducted a case report in Osteomyelitis due to vancomycin-resistant and teicoplanin-resistant Enterococcus faecium (n=1). Linezolid was evaluated on Treatment success and hematological alterations. A hemodialysis patient with osteomyelitis due to vancomycin- and teicoplanin-resistant Enterococcus faecium was successfully treated with linezolid for 6 months despite hematological alterations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: